search
Back to results

Phase IV Study to Evaluate the Efficacy of Lagricel® Ofteno PF Compared to Thealoz® Duo After Photorefractive Keratectomy (PRK) (PRO-037)

Primary Purpose

Photorefractive Keratectomy, Corneal De-epithelialization

Status
Recruiting
Phase
Phase 4
Locations
Mexico
Study Type
Interventional
Intervention
Sodium Hyaluronate Ophthalmic 0.4%
Trehalose 3% / Sodium Hyaluronate Ophthalmic 0.15%
Sponsored by
Laboratorios Sophia S.A de C.V.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Photorefractive Keratectomy

Eligibility Criteria

18 Years - 45 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • - Age ≥ 18 and ≤ 45 years old
  • Being on PRK postoperative day 1 (right eye will be evaluated for efficacy)
  • Presenting a PRK surgical corneal ablation surface of 5.5 to 6.0 mm
  • PRK corneal output ≤ 60 µm
  • Preoperative refraction of -1.0 to -4.5 D of myopia or myopic astigmatism (in this case, the sum of both values with a spherical equivalent no greater than -4.5 D)
  • Being capable of voluntarily grant a signed informed consent.
  • Being willing and able to meet the requirements of the study such as attending programmed visits, treatment plan and other study procedures.
  • Being willing and able to modify the required lifestyle activities.
  • Women in child-bearing age must assure the continuation (start ≥ 30 days prior to informed consent signing) of a hormonal contraceptive method or intrauterine device (IUD) during the study.

Exclusion Criteria:

  • Having suffered any complications during and after PRK surgical procedure previous to inclusion in the study.
  • Use of mitomycin during PRK
  • Being subjected to PRK retreatment of previous history of any other kind of refractive surgery.
  • Pregnancy, breastfeeding or planning to become pregnant during the time of the study
  • Having participated in clinical trials within 30 days prior to signing this study's informed consent form.
  • Having participated previously in this study.
  • Diagnosis of any of the following:

    • Allergic, viral or bacterial conjunctivitis
    • Dry eye
    • Anterior blepharitis
    • Parasite infestation of ocular structures (Demodex, for example)
    • Previous history of ocular herpes
    • Previous history of ocular inflammation (such as uveitis)
    • Corneal or conjunctival ulcers
    • Glaucoma
  • Previous history of drug addiction within the last 2 years previous to signing this study's informed consent form.
  • Having a previous history of any ophthalmological surgical procedure, within the last 3 months prior to the informed consent signing date.
  • Previous history of any medical affliction, acute or chronic (such as Diabetes Mellitus type I/II, autoimmune diseases or HIV), that according to the investigator may increase either the risk to the patient for participating in this study or the risk of interference of the accurate interpretation of results.
  • Use of medications (such as retinoic acid) that according to the investigator's criteria may increase either the risk to the patient for participating in this study or the risk of interference of the accurate interpretation of results.
  • Known hypersensitivity to any of the components of the products used in this study.

Sites / Locations

  • Aris Vision Institute de Guadalajara, S. C.Recruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Group 1; Lagricel® Ofteno PF

Group 2; Thealoz® Duo

Arm Description

Lagricel® Ofteno PF, multidose presentation (sodium hyaluronate 0.4%) Ophthalmic Solution. One drop QID, both eyes (OU) for 14 days.

Thealoz® Duo, (trehalose 3%/sodium hyaluronate 0.15%). Ophthalmic Solution. One drop QID, both eyes (OU) for 14 days.

Outcomes

Primary Outcome Measures

Changes in corneal re-epithelialization (time)
Corneal re-epithelialization will be evaluated through direct observation and photographic recording after application of fluorescein stain. After instillation of a drop of topical anesthetic (tetracaine 0.5%) a fluorescein strip will be applied on the inferior cul de sac while the patient looks upward. Using a slit lamp with magnification of 6x and 16x photographs (at least 6 images for each magnification) will be obtained.
Incidence of adverse events
Presence/absence adverse events, defined as the appearance of any unfavorable reaction in a patient participating in a clinical investigation in which any pharmaceutical product is being administered, regardless of the causal attribution.
Change in Best Corrected Visual Acuity (BCVA)
With the patient's best possible refractive correction, visual acuity will be evaluated through the Snellen chart. Its notation (fraction or decimal) is described as the distance from the chart at which the test is performed, divided by the distance at which a letter equals vertically 5 minutes of arc.

Secondary Outcome Measures

Changes in Ocular Comfort Index
Ocular Comfort Index (OCI) Questionnaire will be used for evaluation of tolerability through incidence and severity of dry eye symptoms in a scale from 0 to 100. Greater scores mean a worse outcome.
Pain perception
Through a questionnaire, patients will be directly questioned about presence and severity of pain and associated symptoms. The scale will be as follows for severity: absent (0), very mild (1), mild (2), moderate (3) and severe (4); and for frequency: never (0), almost never (1), 50% of the time (2), almost all the time (3) and all the time (4).

Full Information

First Posted
January 7, 2021
Last Updated
December 26, 2022
Sponsor
Laboratorios Sophia S.A de C.V.
search

1. Study Identification

Unique Protocol Identification Number
NCT04704518
Brief Title
Phase IV Study to Evaluate the Efficacy of Lagricel® Ofteno PF Compared to Thealoz® Duo After Photorefractive Keratectomy (PRK)
Acronym
PRO-037
Official Title
Phase IV Clinical Study to Evaluate the Efficacy of Lagricel® Ofteno PF Compared to Thealoz® Duo for Corneal Re-epithelialization After Photorefractive Keratectomy (PRK)
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Recruiting
Study Start Date
September 3, 2022 (Actual)
Primary Completion Date
April 30, 2023 (Anticipated)
Study Completion Date
April 30, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Laboratorios Sophia S.A de C.V.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Phase IV comparative, controlled, parallel group, open, randomized multicenter study to evaluate the efficacy of Lagricel® Ofteno PF Compared to Thealoz® Duo. Primary outcome measure is the time of corneal re-epithelialization after PRK surgery. Intervention includes administration of one of the experimental products quater per die (QID) for 14 days.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Photorefractive Keratectomy, Corneal De-epithelialization

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
Comparative, controlled, parallel group, open, randomized multicenter study
Masking
None (Open Label)
Allocation
Randomized
Enrollment
96 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Group 1; Lagricel® Ofteno PF
Arm Type
Experimental
Arm Description
Lagricel® Ofteno PF, multidose presentation (sodium hyaluronate 0.4%) Ophthalmic Solution. One drop QID, both eyes (OU) for 14 days.
Arm Title
Group 2; Thealoz® Duo
Arm Type
Active Comparator
Arm Description
Thealoz® Duo, (trehalose 3%/sodium hyaluronate 0.15%). Ophthalmic Solution. One drop QID, both eyes (OU) for 14 days.
Intervention Type
Drug
Intervention Name(s)
Sodium Hyaluronate Ophthalmic 0.4%
Other Intervention Name(s)
Lagricel® Ofteno PF, PRO-037
Intervention Description
Topical ophthalmic administration of one drop of Lagricel® Ofteno PF QID.
Intervention Type
Drug
Intervention Name(s)
Trehalose 3% / Sodium Hyaluronate Ophthalmic 0.15%
Other Intervention Name(s)
Thealoz® Duo
Intervention Description
Topical ophthalmic administration of one drop of Thealoz® Duo QID.
Primary Outcome Measure Information:
Title
Changes in corneal re-epithelialization (time)
Description
Corneal re-epithelialization will be evaluated through direct observation and photographic recording after application of fluorescein stain. After instillation of a drop of topical anesthetic (tetracaine 0.5%) a fluorescein strip will be applied on the inferior cul de sac while the patient looks upward. Using a slit lamp with magnification of 6x and 16x photographs (at least 6 images for each magnification) will be obtained.
Time Frame
Days: 1 (baseline visit), 2 (±1) (first follow-up visit), 3 (±1) (second follow-up visit), 7 (±1) (third follow-up visit)
Title
Incidence of adverse events
Description
Presence/absence adverse events, defined as the appearance of any unfavorable reaction in a patient participating in a clinical investigation in which any pharmaceutical product is being administered, regardless of the causal attribution.
Time Frame
Day: 15 (±1) (final visit)
Title
Change in Best Corrected Visual Acuity (BCVA)
Description
With the patient's best possible refractive correction, visual acuity will be evaluated through the Snellen chart. Its notation (fraction or decimal) is described as the distance from the chart at which the test is performed, divided by the distance at which a letter equals vertically 5 minutes of arc.
Time Frame
Days: 1 (baseline visit), 2 (±1) (first follow-up visit), 3 (±1) (second follow-up visit), 7 (±1) (third follow-up visit) and 15 (±1) (final visit)
Secondary Outcome Measure Information:
Title
Changes in Ocular Comfort Index
Description
Ocular Comfort Index (OCI) Questionnaire will be used for evaluation of tolerability through incidence and severity of dry eye symptoms in a scale from 0 to 100. Greater scores mean a worse outcome.
Time Frame
Days: 7 (±1) (third follow-up visit) and 15 (±1) (final visit)
Title
Pain perception
Description
Through a questionnaire, patients will be directly questioned about presence and severity of pain and associated symptoms. The scale will be as follows for severity: absent (0), very mild (1), mild (2), moderate (3) and severe (4); and for frequency: never (0), almost never (1), 50% of the time (2), almost all the time (3) and all the time (4).
Time Frame
Days: 1 (baseline visit), 2 (±1) (first follow-up visit), 3 (±1) (second follow-up visit), 7 (±1) (third follow-up visit) and 15 (±1) (final visit)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: - Age ≥ 18 and ≤ 45 years old Being on PRK postoperative day 1 (right eye will be evaluated for efficacy) Presenting a PRK surgical corneal ablation surface of 5.5 to 6.0 mm PRK corneal output ≤ 60 µm Preoperative refraction of -1.0 to -4.5 D of myopia or myopic astigmatism (in this case, the sum of both values with a spherical equivalent no greater than -4.5 D) Being capable of voluntarily grant a signed informed consent. Being willing and able to meet the requirements of the study such as attending programmed visits, treatment plan and other study procedures. Being willing and able to modify the required lifestyle activities. Women in child-bearing age must assure the continuation (start ≥ 30 days prior to informed consent signing) of a hormonal contraceptive method or intrauterine device (IUD) during the study. Exclusion Criteria: Having suffered any complications during and after PRK surgical procedure previous to inclusion in the study. Use of mitomycin during PRK Being subjected to PRK retreatment of previous history of any other kind of refractive surgery. Pregnancy, breastfeeding or planning to become pregnant during the time of the study Having participated in clinical trials within 30 days prior to signing this study's informed consent form. Having participated previously in this study. Diagnosis of any of the following: Allergic, viral or bacterial conjunctivitis Dry eye Anterior blepharitis Parasite infestation of ocular structures (Demodex, for example) Previous history of ocular herpes Previous history of ocular inflammation (such as uveitis) Corneal or conjunctival ulcers Glaucoma Previous history of drug addiction within the last 2 years previous to signing this study's informed consent form. Having a previous history of any ophthalmological surgical procedure, within the last 3 months prior to the informed consent signing date. Previous history of any medical affliction, acute or chronic (such as Diabetes Mellitus type I/II, autoimmune diseases or HIV), that according to the investigator may increase either the risk to the patient for participating in this study or the risk of interference of the accurate interpretation of results. Use of medications (such as retinoic acid) that according to the investigator's criteria may increase either the risk to the patient for participating in this study or the risk of interference of the accurate interpretation of results. Known hypersensitivity to any of the components of the products used in this study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Alejandra Sanchez-Rios, MD
Phone
+52 3330004200
Ext
1190
Email
alejandra.sanchez@sophia.com.mx
Facility Information:
Facility Name
Aris Vision Institute de Guadalajara, S. C.
City
Guadalajara
State/Province
Jalisco
Country
Mexico
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Miguel Montes, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Phase IV Study to Evaluate the Efficacy of Lagricel® Ofteno PF Compared to Thealoz® Duo After Photorefractive Keratectomy (PRK)

We'll reach out to this number within 24 hrs